Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Curis ( (CRIS) ) has provided an announcement.
Curis, Inc. is facing a potential delisting from the Nasdaq Capital Market due to non-compliance with the market value of listed securities requirement, which mandates a minimum of $35 million. After receiving a delisting notice on August 21, 2025, Curis requested a hearing, which temporarily halted the delisting process. On October 20, 2025, Nasdaq granted Curis an exception until November 14, 2025, to regain compliance. The company must notify Nasdaq of any significant developments during this period, but there is no guarantee of maintaining its listing.
The most recent analyst rating on (CRIS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.
Spark’s Take on CRIS Stock
According to Spark, TipRanks’ AI Analyst, CRIS is a Neutral.
Curis’ overall stock score is primarily impacted by its weak financial performance and valuation, reflecting ongoing profitability and solvency challenges. While the earnings call provided some positive clinical trial updates, the limited cash runway and regulatory uncertainties remain significant risks. Technical analysis also indicates a bearish trend, further weighing down the score.
To see Spark’s full report on CRIS stock, click here.
More about Curis
Average Trading Volume: 67,386
Technical Sentiment Signal: Strong Sell
Current Market Cap: $19.12M
Find detailed analytics on CRIS stock on TipRanks’ Stock Analysis page.